A security guard gestures as he stands outside a closed Ranbaxy Laboratories Ltd. plant at Toansa village in the northern Indian state of Punjab February 27, 2014. A spate of regulatory warnings for ... more 
A security guard gestures as he stands outside a closed Ranbaxy Laboratories Ltd. plant at Toansa village in the northern Indian state of Punjab February 27, 2014. A spate of regulatory warnings for India's generic drug manufacturers will add a new emphasis on the quality of such medicines in an industry long dominated by the ability to deliver treatments as cheaply as possible, analysts say. The biggest setback for India's $14 billion a year generic drug industry came in January, when the FDA banned imports from all the Indian plants of Ranbaxy Laboratories Ltd, India's No. 1 drugmaker by sales, over repeated production quality lapses. While generic drugmakers based in the United States and elsewhere have also been cited by the U.S. Food and Drug Administration for quality control problems over the years, India's industry has come under fresh scrutiny recently as the agency steps up its inspections there. Picture taken February 27, 2014. To match INDIA/DRUGMAKER-WOES REUTERS/Ajay Verma (INDIA - Tags: DRUGS SOCIETY HEALTH) less 
1 / 17
Reuters | Photo By AJAY VERMA / REUTERS
Wed, Mar 26, 2014 1:21 PM EDT